Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.

Saved in:
Bibliographic Details
Title: Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.
Authors: Griffett K; Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States., Burris TP; The University of Florida Genetics Institute, Gainesville, FL, United States.
Source: Frontiers in medicine [Front Med (Lausanne)] 2023 Feb 02; Vol. 10, pp. 1102469. Date of Electronic Publication: 2023 Feb 02 (Print Publication: 2023).
Publication Type: Journal Article; Review
Journal Info: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2296-858X
DOI:10.3389/fmed.2023.1102469